| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
Medusa Medical Technologies Inc is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sleep Rx is a Visalia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.